DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and ...

Clinical research company IQVIA (NYSE: IQV) reported in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The ...

While the newly renamed IQVIA (NYSE: IQV) has been busy rolling out the first offering of its integration-focused technology for the commercial side of the pharmaceutical industry, offerings for the ...

IQVIA Holdings Inc. IQV yesterday unveiled a clinical trial technology platform, One Home for Sites. The platform streamlines the process of management of trials by acting as a single sign-on and a ...

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) is a global leader in healthcare data, analytics, technology, and clinical research services. With a market cap of $34.6 billion, the company ...

New multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline ...

Clinical research company IQVIA (NYSE: IQV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales ...

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

IQVIA reaffirmed its full-year 2025 guidance, narrowing the ranges to revenue between $16.15 billion and $16.25 billion and adjusted earnings per share between $11.85 and $11.95, in line with analyst ...

Nov 1 (Reuters) - IQVIA Holdings (IQV.N), opens new tab cut its full-year profit forecast on Wednesday, citing weakness in demand for its analytics and medical technology solutions along with the ...

Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.9x Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA) 4.5x ...